Warning: file_get_contents(http://tehnika-news.ru/shells.txt): failed to open stream: Connection refused in /var/sites/p/paperbomb.com/public_html/meds2/1/index.php on line 2
besponsa prescribing information

besponsa prescribing information

Перейти к контенту

Главное меню:

Разное
besponsa prescribing information
Welcome to BESPONSA® | BESPONSA®, Reference ID: 4140675 - Food and Drug Administration, About BESPONSA® | BESPONSA®, BESPONSA™ (inotuzumab ozogamicin) | R/R B-Cell ALL , Drug Trials Snapshots: BESPONSA, HIGHLIGHTS OF PRESCRIBING INFORMATION , Besponsa Monograph for Professionals - Drugs.com, BILLING AND CODING INFORMATION FOR HOSPITAL OUTPATIENT, FDA approves new treatment for adults with relapsed or .
BESPONSA can cause liver problems that can be severe, life-threatening, or fatal, including a condition called veno-occlusive disease (VOD). This condition can occur during treatment with BESPONSA or following subsequent treatment with a stem cell transplant. This condition was more common in patients who had elevated liver tests or who received dual alkylating agents in preparation for their stem cell transplant. Patients may be at a higher risk of VOD if they: . BESPONSA is a prescription medicine used to treat adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). It is not known if BESPONSA is safe and effective in children under 18 years of age.. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use BESPONSA™ safely and effectively. See full prescribing information for BESPONSA. BESPONSA (inotuzumab ozogamicin) for injection, for intravenous use Initial U.S. Approval: 2017 . WARNING: HEPATOTOXICITY, INCLUDING HEPATIC VENO­ OCCLUSIVE DISEASE (VOD) (ALSO KNOWN AS SINUSOIDAL OBSTRUCTION .
BESPONSA is a type of medicine called an antibody-drug conjugate. BESPONSA is designed to find and attach to a specific protein, called CD22, found on leukemia cells BESPONSA is designed to find and attach to a specific protein, called CD22, found on leukemia cells. References. BESPONSA Prescribing Information. New York, NY: Pfizer Inc. Kantarjian HM, DeAngelo DJ, Stelljes M, et al. lnotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia.. BESPONSA Prescribing Information Table 5. Laboratory Abnormalities in Patients with Relapsed or Refractory B-Cell Precursor ALL Who Received BESPONSA or Investigator’s Choice of Chemotherapy . 1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use BESPONSA™ safely and effectively. See full prescribing information for. Besponsa reference guide for safe and effective use from the American Society of Health-System Pharmacists (AHFS DI).. Please click here to see full Prescribing Information, including BOXED WARNING, for BESPONSA. BESPONSA for injection is a white to off-white lyophilized powder supplied.
 
Copyright 2019. All rights reserved.
Назад к содержимому | Назад к главному меню